Chargement en cours...
Bevacizumab Dose Affects the Severity of Adverse Events in Gynecologic Malignancies
In this retrospective study, we investigated adverse events and outcomes in patients treated with bevacizumab for ovarian, fallopian tube, or primary peritoneal cancers at a single hospital. We determined the cumulative incidences of various bevacizumab-related adverse events and the correlation bet...
Enregistré dans:
| Publié dans: | Front Pharmacol |
|---|---|
| Auteurs principaux: | , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Frontiers Media S.A.
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6498445/ https://ncbi.nlm.nih.gov/pubmed/31105567 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2019.00426 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|